X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (938) 938
Publication (98) 98
Newsletter (82) 82
Newspaper Article (35) 35
Book Review (15) 15
Book Chapter (11) 11
Transcript (10) 10
Dissertation (3) 3
Trade Publication Article (2) 2
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
pertuzumab (983) 983
trastuzumab (601) 601
oncology (553) 553
breast cancer (542) 542
index medicus (511) 511
humans (477) 477
female (402) 402
cancer (311) 311
breast neoplasms - drug therapy (310) 310
chemotherapy (280) 280
her2 (258) 258
open-label (223) 223
lapatinib (210) 210
care and treatment (194) 194
receptor, erbb-2 - metabolism (181) 181
docetaxel (178) 178
breast neoplasms - pathology (174) 174
metastasis (172) 172
research (168) 168
therapy (155) 155
antineoplastic combined chemotherapy protocols - therapeutic use (143) 143
middle aged (142) 142
skin and connective tissue diseases (138) 138
survival (138) 138
receptor, erbb-2 - antagonists & inhibitors (133) 133
epidermal growth factor (128) 128
antineoplastic agents - therapeutic use (126) 126
monoclonal-antibody (121) 121
aged (120) 120
adult (119) 119
erbb-2 protein (118) 118
breast neoplasms - metabolism (114) 114
drug therapy (114) 114
treatment outcome (112) 112
health aspects (109) 109
multicenter (107) 107
safety (106) 106
antibodies, monoclonal, humanized - therapeutic use (101) 101
analysis (100) 100
efficacy (100) 100
cancer therapies (99) 99
medicine & public health (99) 99
animals (95) 95
antibodies, monoclonal, humanized - administration & dosage (93) 93
combination (91) 91
tumors (89) 89
clinical trials (88) 88
neoadjuvant therapy (86) 86
metastatic breast-cancer (85) 85
phase-ii (83) 83
women (83) 83
adjuvant chemotherapy (82) 82
pharmacology & pharmacy (81) 81
receptor, erbb-2 - genetics (81) 81
trial (81) 81
neoplasms (78) 78
patients (74) 74
trastuzumab - administration & dosage (74) 74
disease-free survival (71) 71
breast-cancer (69) 69
metastatic breast cancer (69) 69
breast neoplasms - genetics (67) 67
growth-factor receptor (66) 66
monoclonal antibodies (66) 66
oncology, experimental (66) 66
adjuvant treatment (64) 64
hematology, oncology and palliative medicine (64) 64
phase-ii trial (64) 64
plus trastuzumab (64) 64
trastuzumab emtansine (64) 64
neoadjuvant chemotherapy (62) 62
paclitaxel (62) 62
pertuzumab plus trastuzumab (62) 62
plus (62) 62
double-blind (61) 61
immunotherapy (61) 61
metastases (61) 61
receptor (61) 61
t-dm1 (60) 60
adjuvant trastuzumab (59) 59
cell line, tumor (59) 59
resistance (59) 59
dimerization inhibitor (58) 58
medical research (58) 58
antineoplastic combined chemotherapy protocols - adverse effects (57) 57
molecular targeted therapy (57) 57
antineoplastic agents (56) 56
obstetrics & gynecology (56) 56
article (55) 55
prognosis (55) 55
antimitotic agents (54) 54
pathological complete response (54) 54
antibodies, monoclonal, humanized (53) 53
antibodies, monoclonal, humanized - adverse effects (53) 53
breast neoplasms - mortality (50) 50
trastuzumab - therapeutic use (50) 50
antineoplastic agents - pharmacology (49) 49
neoplasm metastasis (49) 49
medical prognosis (48) 48
aged, 80 and over (46) 46
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1038) 1038
French (16) 16
German (11) 11
Czech (3) 3
Spanish (2) 2
Bosnian (1) 1
Chinese (1) 1
Japanese (1) 1
Polish (1) 1
Russian (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 05/2015, Volume 33, Issue 15, pp. 1712 - 1712
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 09/2016, Volume 34, Issue 26, pp. 3227 - 3227
Journal Article
PloS one, ISSN 1932-6203, 2019, Volume 14, Issue 5, p. e0217716
[This corrects the article DOI: 10.1371/journal.pone.0216095.]. 
Pertuzumab | ErbB-2 protein | Trastuzumab
Journal Article
The Oncologist, ISSN 1083-7159, 02/2019, Volume 24, Issue 2, pp. e80 - e82
Human epidermal growth factor receptor 2 (HER2)‐targeted antibodies, including pertuzumab and trastuzumab, improve overall survival and progression‐free... 
TRASTUZUMAB | ONCOLOGY | PERTUZUMAB | DOCETAXEL | STRESS-INDUCED CARDIOMYOPATHY
Journal Article
Oncotarget, ISSN 1949-2553, 2017, Volume 8, Issue 34, pp. 56921 - 56931
We addressed trastuzumab emtansine (T-DM1) efficacy in HER2+ metastatic breast cancer patients treated in real-world practice, and its activity in... 
HER2 positive | Metastatic breast cancer | T-DM1 | Previous pertuzumab | Real-world | PHASE-II | MONOCLONAL-ANTIBODY | PERTUZUMAB | DOCETAXEL | CHEMOTHERAPY | CELL BIOLOGY | real-world | GROWTH-FACTOR RECEPTOR | THERAPY | metastatic breast cancer | LAPATINIB PLUS CAPECITABINE | CLINICAL-PRACTICE | previous pertuzumab
Journal Article
British Journal of Cancer, ISSN 0007-0920, 11/2014, Volume 111, Issue 10, pp. 1888 - 1898
Journal Article
Oncotarget, ISSN 1949-2553, 08/2018, Volume 9, Issue 61, pp. 31915 - 31919
Targeting of HER2-positive tumors with trastuzumab has shown to improve survival in early stage and advanced breast cancer. The addition of pertuzumab, another... 
Breast cancer | TDM1 | Pertuzumab | HER2 | Trastuzumab
Journal Article
ANNALS OF ONCOLOGY, ISSN 0923-7534, 06/2019, Volume 30, Issue 6, pp. 921 - 926
Background In human epidermal growth factor receptor 2 (HER2+) breast cancers, neoadjuvant trials of chemotherapy plus anti-HER2 treatment consistently showed... 
early breast cancer | neoadjuvant | MULTICENTER | PERTUZUMAB PLUS TRASTUZUMAB | SAFETY | PHASE-II | ENDOCRINE THERAPY | OPEN-LABEL | BIOMARKER ANALYSIS | CHEMOTHERAPY | trastuzumab | LAPATINIB | HER2-positive breast cancer | ONCOLOGY | pertuzumab | EARLY BREAST-CANCER | Original
Journal Article
ONCOLOGY-NEW YORK, ISSN 0890-9091, 11/2015, Volume 29, Issue 11, pp. 797 - 797
Journal Article
JNCCN Journal of the National Comprehensive Cancer Network, ISSN 1540-1405, 12/2015, Volume 13, Issue 12, pp. 1475 - 1485
These NCCN Guideline Insights highlight the important updates to the systemic therapy recommendations in the 2016 NCCN Guidelines for Breast Cancer. In the... 
OVARIAN SUPPRESSION | 1ST-LINE TREATMENT | PERTUZUMAB PLUS TRASTUZUMAB | ONCOLOGY | PREOPERATIVE THERAPY | DOUBLE-BLIND | LETROZOLE | POSTMENOPAUSAL WOMEN | CHEMOTHERAPY | NEOADJUVANT | ANASTROZOLE
Journal Article
11/2009
The human epidermal growth factor receptor 2 (HER2) is overexpressed in 20% of breast cancers (BCs) and confers an aggressive tumour phenotype with a poor... 
Pertuzumab | Molecular Imaging | 0419 | Nuclear Medicine | HER2 | Breast Cancer | Trastuzumab
Dissertation
Current oncology (Toronto, Ont.), ISSN 1198-0052, 12/2018, Volume 25, Issue 6, pp. 355 - 357
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2019, Volume 37, Issue 2, pp. 125 - 134
PurposeClinical evidence demonstrating the effectiveness of systemic therapy for advanced salivary duct carcinoma (SDC) is lacking because of the disease's... 
ANDROGEN RECEPTOR | PLUS DOCETAXEL | CARBOPLATIN | PHARMACOKINETICS | ONCOLOGY | GLAND CARCINOMAS | COMBINATION | PERTUZUMAB | CANCER | CHEMOTHERAPY | PACLITAXEL
Journal Article
Asia-Pacific Journal of Clinical Oncology, ISSN 1743-7555, 2019
Internationally, there has recently been growing interest in the use of neoadjuvant pertuzumab and trastuzumab in patients with non-metastatic HER-2 positive... 
neoadjuvant | pathological complete response | pertuzumab | HER2 | taxane
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.